Your browser doesn't support javascript.
loading
A cell permeable bimane-constrained PCNA-interacting peptide.
Horsfall, Aimee J; Vandborg, Beth A; Kikhtyak, Zoya; Scanlon, Denis B; Tilley, Wayne D; Hickey, Theresa E; Bruning, John B; Abell, Andrew D.
Afiliación
  • Horsfall AJ; Institute of Photonics and Advanced Sensing (IPAS), The University of Adelaide Adelaide South Australia 5005 Australia john.bruning@adelaide.edu.au andrew.abell@adelaide.edu.au.
  • Vandborg BA; School of Physical Sciences, The University of Adelaide Adelaide South Australia 5005 Australia.
  • Kikhtyak Z; Australian Research Council Centre of Excellence for Nanoscale BioPhotonics (CNBP) Australia.
  • Scanlon DB; Institute of Photonics and Advanced Sensing (IPAS), The University of Adelaide Adelaide South Australia 5005 Australia john.bruning@adelaide.edu.au andrew.abell@adelaide.edu.au.
  • Tilley WD; School of Biological Sciences, The University of Adelaide Adelaide South Australia 5005 Australia.
  • Hickey TE; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide Adelaide South Australia 5005 Australia.
  • Bruning JB; Institute of Photonics and Advanced Sensing (IPAS), The University of Adelaide Adelaide South Australia 5005 Australia john.bruning@adelaide.edu.au andrew.abell@adelaide.edu.au.
  • Abell AD; School of Physical Sciences, The University of Adelaide Adelaide South Australia 5005 Australia.
RSC Chem Biol ; 2(5): 1499-1508, 2021 Oct 07.
Article en En | MEDLINE | ID: mdl-34704055
ABSTRACT
The human sliding clamp protein known as proliferating cell nuclear antigen (PCNA) orchestrates DNA-replication and -repair and as such is an ideal therapeutic target for proliferative diseases, including cancer. Peptides derived from the human p21 protein bind PCNA with high affinity via a 310-helical binding conformation and are known to shut down DNA-replication. Here, we present studies on short analogues of p21 peptides (143-151) conformationally constrained with a covalent linker between i, i + 4 separated cysteine residues at positions 145 and 149 to access peptidomimetics that target PCNA. The resulting macrocycles bind PCNA with K D values ranging from 570 nM to 3.86 µM, with the bimane-constrained peptide 7 proving the most potent. Subsequent X-ray crystallography and computational modelling studies of the macrocyclic peptides bound to PCNA indicated only the high-affinity peptide 7 adopted the classical 310-helical binding conformation. This suggests the 310-helical conformation is critical to high affinity PCNA binding, however NMR secondary shift analysis of peptide 7 revealed this secondary structure was not well-defined in solution. Peptide 7 is cell permeable and localised to the cell cytosol of breast cancer cells (MDA-MB-468), revealed by confocal microscopy showing blue fluorescence of the bimane linker. The inherent fluorescence of the bimane moiety present in peptide 7 allowed it to be directly imaged in the cell uptake assay, without attachment of an auxiliary fluorescent tag. This highlights a significant benefit of using a bimane constraint to access conformationally constrained macrocyclic peptides. This study identifies a small peptidomimetic that binds PCNA with higher affinity than previous reported p21 macrocycles, and is cell permeable, providing a significant advance toward development of a PCNA inhibitor for therapeutic applications.

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: RSC Chem Biol Año: 2021 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: RSC Chem Biol Año: 2021 Tipo del documento: Article